Merck & Co Inc

NYSE:MRK   3:59:59 PM EDT
78.90
-0.93 (-1.16%)
4:11:40 PM EDT: $78.79 -0.11 (-0.14%)
Products

FDA Approves Expanded Indication For Merck's Keytruda In Adult Patients With Relapsed Or Refractory Classical Hodgkin Lymphoma

Published: 10/15/2020 11:46 GMT
Merck & Co Inc (MRK) - FDA Approves Expanded Indication for Merck’s Keytruda® (pembrolizumab) in Adult Patients With Relapsed Or Refractory Classical Hodgkin Lymphoma (chl).
FDA Approves Expanded Indication for Merck’s Keytruda® (pembrolizumab) in Adult Patients With Relapsed Or Refractory Classical Hodgkin Lymphoma (chl).
Merck & Co Inc - Keytruda Also Approved for Pediatric Patients With Refractory Chl, Or Chl That Has Relapsed After Two Or More Lines of Therapy.
Merck - Approval Based on Phase 3 Keynote-204 Trial in Which Keytruda Reduced Risk of Disease Progression Or Death by 35% Versus Brentuximab Vedotin.